MA-IBASIS
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and KPN, the Netherlands’ leading telecom company, announced today that they have renewed their outsourcing agreement for Voice and Mobile services for three years.
Since its sale by KPN in 2019, iBASIS and its global team have been dedicated to bringing KPN best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. Cost stability, capacity planning, and fraud prevention have been instrumental in sustaining the Dutch operator’s traffic growth.
The renewal underscores the success of iBASIS’ model and long-term relationship with managing KPN’s international traffic growth, including IPX cooperation to handle the surge in mobile data traffic. iBASIS reports an 80% year-on-year growth in Diameter traffic, which has enabled KPN to deliver reliable, high-speed data roaming services to its subscribers. The network scalability has been critical in meeting the explosive 4G and 5G mobile data roaming demand, including traffic peaks resulting from the rise of M2M connections.
“iBASIS has been a trusted partner of KPN for the past six years, managing our international voice and mobile services. Leveraging their consolidation model and economies of scale, we outsource nearly 100% of our voice business to iBASIS. Their partner program is focused on delivering quality, transparency, and actionable business insights,” said Michel van Wissen, Executive Vice President, Wholesale, KPN. “We have extended our partnership for another three years. Our excitement is based on proven past successes and on the innovation iBASIS continues to demonstrate in meeting the challenges providers face now and in the future.”
Outsourcing international voice and mobile services also enables KPN to focus on its retail and wholesale business as well as technology initiatives associated with developing these segments.
“We enjoy a strong and mutually beneficial relationship with KPN on voice and mobile services,” added Edwin van Ierland, CEO, iBASIS Voice & Mobile Data. “We are more than a supplier; we are a growth partner. As such, we are very motivated to help KPN leverage our global platform and capabilities to the fullest. The renewal illustrates our excellent relationship, centered on transparency and open communication. It again demonstrates that the outsourcing model chosen by KPN is highly effective.”
“KPN’s three-year renewal is the recognition of iBASIS/Tofane past and future excellence thanks to our unique mix of scale, innovation, and entrepreneurship,” said Alexandre Pébereau, Group CEO and Founder, Tofane Global. “Our performance is recognized again by ROCCO as a top Tier One International Voice Carrier,* Telegeography Fourth Voice Carrier,** and First Independent Carrier.”
In 2023, iBASIS was ranked by 227 MNOs as the top Tier One International Voice Carrier for Performance, Performance+, Leadership, General Rating, and Overall Rating, with the highest results for Global Presence, Local Expertise, R&D Investment, Trusted, Innovative, Dynamic, and Enabler.*
*ROCCO Research: International Voice Carrier Market Impact Report 2023
**Telegeography International Voice Report 2024
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT.
About KPN
KPN has been the leading provider of telecommunications and IT services in the Netherlands for almost 140 years. Everyone in the Netherlands uses the KPN network on a daily basis, either directly or indirectly, from the high-speed fibre networks in the ground to payment card machines in shops, or the matrix boards above the motorways. Via the network of the Netherlands, in which KPN continuously invests by rolling out fibre and the introduction of new technologies such as the 5G mobile network, KPN serves consumers and business customers with services for telephony, data, television, internet-of-things, cloud, workplaces and security. KPN has an open network on which other providers also offer services. More information is available at www.kpn.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220905856/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom